Compass Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Compass Therapeutics, Inc. on August 17, 2022. The Company is a biopharmaceutical firm incorporated in Delaware, with its principal executive offices located in Boston, Massachusetts. The report addresses a specific corporate governance event occurring during this period.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the resignation of Stephen Squinto, Ph.D., from the Board of Directors and all associated committees. His resignation is effective August 31, 2022. Dr. Squinto has served on the Board since 2015, initially representing an early investor. The Company stated that the resignation was not the result of any disagreement regarding operations, policies, or practices, but rather due to Dr. Squinto pursuing other professional endeavors.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks, contingencies, or unusual items related to financial operations were disclosed in this document.
Key Facts for Investor Verification
- Stephen Squinto, Ph.D., is resigning from the Board of Directors effective August 31, 2022.
- The resignation is voluntary and not related to any disagreement with the Company.
- Dr. Squinto has been a Board member since 2015.
- The Company has not announced a replacement director in this filing.